Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Transcenta Holding Limited (6628.HK)
Suzhou, CN
Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacturing, and commercialization of therapeutic agents within the People's Republic of China and the United States. The company boasts a comprehensive pipeline of drug candidates. In oncology, its key developments include: MSB2311, a humanized PD-L1 monoclonal antibody, currently in Phase Ib/IIa trials for various solid tumors, particularly those with high tumor mutational burden (TMB-H). TST001, a humanized claudin 18.2 monoclonal antibody undergoing Phase II clinical development for solid tumors, such as gastric cancer. TST005, a bifunctional PD-L1/TGF-ß antibody in Phase Ia clinical trials for solid tumors, including certain types of lung cancer. TST010, an antibody designed to target regulatory T cells, aiming to bolster T cell-mediated anti-tumor activity. TST003, an antibody addressing a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells exhibiting a mesenchymal phenotype. TST006, a bispecific antibody targeting both claudin 18.2 and PD-L1. TST008, a trifunctional antibody that combines a MASP2 antibody with a truncated transmembrane activator and CAML interactor protein. MSB0254, a humanized VEGFR-2 monoclonal antibody also in Phase Ib/IIa clinical studies for solid tumors. Beyond cancer, Transcenta is advancing: TST002 (Blosozumab), a humanized sclerostin monoclonal antibody for the treatment of osteoporosis. TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) monoclonal antibody intended for IgA kidney diseases. The company has forged collaboration agreements with prominent organizations, including Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. Founded in 2010 as MabSpace International Limited, the entity adopted the name Transcenta Holding Limited in June 2019. Its corporate headquarters are located in Suzhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.64% | -18.97% | -29.15% | -31.60% | -41.91% | -25.47% | -2.47% | -69.38% | -88.07% | -88.07% | -88.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-35.7% Q2'25: -40.6% (vs Q2'24)
-
EPS growth Biotechnology: +29.7%+33.3% ★ Q2'25: +18.8% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,395.0% Q2'25: -2,951.6% (vs Q2'24)
-
EBIT margin Biotechnology: +0.0%-2,699.8% Q2'25: -4,211.6% (vs Q2'24)
-
ROIC Biotechnology: -16.1%-26.8% Q2'25: -31.3% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%+2.3% ★ Q2'25: +0.3% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.82× Q2'25: -0.68× (vs Q2'24)
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
50.24M
est: 50.05M (+0.4%)
|
101.89M
est: 68.85M (+48.0%)
|
53.85M
est: 20.77M (+159.3%)
|
11.26M
est: 9.14M (+23.3%)
|
7.24M
est: 11.73M (-38.3%)
|
13.45M
13.45M – 13.45M
+14.6% YoY
|
30.74M
29.74M – 31.74M
+128.6% YoY
|
335.57M
335.57M – 335.57M
+991.7% YoY
|
| EBITDA |
-1.65B
est: -50.05M (-3,192.7%)
|
-334.09M
est: -68.85M (-385.3%)
|
-393.01M
est: -20.77M (-1,792.2%)
|
-233.12M
est: -9.14M (-2,451.9%)
|
-153.11M
est: -11.73M (-1,204.9%)
|
-13.45M
-13.45M – -13.45M
-14.6% YoY
|
-30.74M
-31.74M – -29.74M
-128.6% YoY
|
-335.57M
-335.57M – -335.57M
-991.7% YoY
|
| EBIT |
-1.70B
est: -50.05M (-3,297.5%)
|
-389.36M
est: -68.85M (-465.5%)
|
-446.80M
est: -20.77M (-2,051.1%)
|
-280.55M
est: -9.14M (-2,971.2%)
|
-195.54M
est: -11.73M (-1,566.5%)
|
-13.45M
-13.45M – -13.45M
-14.6% YoY
|
-30.74M
-31.74M – -29.74M
-128.6% YoY
|
-335.57M
-335.57M – -335.57M
-991.7% YoY
|
| Net Income |
-1.72B
est: -2.03B (+15.7%)
|
-406.75M
est: -471.47M (+13.7%)
|
-462.57M
est: -340.35M (-35.9%)
|
-290.29M
est: -291.05M (+0.3%)
|
-198.45M
est: -271.35M (+26.9%)
|
-278.51M
-278.51M – -278.51M
-2.6% YoY
|
-282.49M
-282.49M – -282.49M
-1.4% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
89.78M
est: 63.41M (+41.6%)
|
49.06M
est: 87.22M (-43.7%)
|
49.87M
est: 56.46M (-11.7%)
|
30.64M
est: 24.83M (+23.4%)
|
55.59M
est: 31.89M (+74.3%)
|
36.56M
36.56M – 36.56M
+14.6% YoY
|
83.55M
80.84M – 86.27M
+128.6% YoY
|
912.15M
912.15M – 912.15M
+991.7% YoY
|
| EPS |
-9.34
est: -5.03 (-85.9%)
|
-0.97
est: -1.16 (+16.7%)
|
-1.14
est: -0.82 (-38.7%)
|
-0.72
est: -0.70 (-2.5%)
|
-0.48
est: -0.66 (+26.7%)
|
-0.67
-0.67 – -0.67
-2.6% YoY
|
-0.68
-0.68 – -0.68
-1.4% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 9.5K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xueming Qian | Executive Chairman & Chief Executive Officer | 3M | — |
| Li Xu | Head of CDx, Member of Scientific Advisory Board, Strategic Advisor to Chief Executive Officer & Non-Executive Director | 2M | — |
| Fan Zhang | SVP of Process Development | — | — |
| Kwan Wai Leung | Company Secretary | — | female |
| Tyler Marciniak | SVP of Capital Markets, Investor Relations & Corporate Communications | — | male |
| Wei Wang | Vice President of Investor Relations & Capital Markets Department and Secretary to the Board | — | female |
| Weiwei Liang | Acting Chief Financial Officer, Senior Vice President of Business Development Transaction & Corporate Strategy | — | male |
| Wen-I Chang | Senior Vice President of Oncology Franchise Strategy | — | — |
| Charlie Qi | Chief Medical Officer, Executive VP & Head of Global R&D | — | — |
| Yi Gu | Senior Vice President & Head of Research | — | — |
| Christopher Hwang | Head of Global Partnerships for HiCB Platform & Member of Scientific Advisory Board | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6628.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
